Importantly, the temporal alignment between VEGF’s peak at Day 14 (285.44 ± 50.0 pg/mL, Table 4) and maximal improvements in pain and function supports VEGF’s role as a central angiogenic driver in resolving hypoxia and chronic inflammation, two pathophysiological hallmarks of tenosynovitis [49]. Here, VEGFA is linked to tenosynovitis.